Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Cash & Equivalents: 2013-2025

Historic Cash & Equivalents for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to $103.4 million.

  • Coherus Oncology's Cash & Equivalents rose 5.80% to $103.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.4 million, marking a year-over-year increase of 5.80%. This contributed to the annual value of $126.0 million for FY2024, which is 22.45% up from last year.
  • According to the latest figures from Q3 2025, Coherus Oncology's Cash & Equivalents is $103.4 million, which was down 52.35% from $216.9 million recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Cash & Equivalents peaked at $417.2 million during Q4 2021, and registered a low of $16.1 million during Q1 2023.
  • Over the past 3 years, Coherus Oncology's median Cash & Equivalents value was $102.9 million (recorded in 2023), while the average stood at $119.8 million.
  • As far as peak fluctuations go, Coherus Oncology's Cash & Equivalents plummeted by 95.04% in 2023, and later skyrocketed by 1,509.01% in 2024.
  • Coherus Oncology's Cash & Equivalents (Quarterly) stood at $417.2 million in 2021, then slumped by 84.77% to $63.5 million in 2022, then surged by 61.91% to $102.9 million in 2023, then increased by 22.45% to $126.0 million in 2024, then increased by 5.80% to $103.4 million in 2025.
  • Its last three reported values are $103.4 million in Q3 2025, $216.9 million for Q2 2025, and $82.4 million during Q1 2025.